コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 bacteriostatic chemical agents to the lower urinary system.
2 iated with development and patterning of the urinary system.
3 bladder tumors, the most common tumor in the urinary system.
4 ecially involving diseases of the kidney and urinary system.
5 nsible for cases involving predominantly the urinary system.
6 rticular, mechanosensory transduction in the urinary system.
7 tem, digestive tract, respiratory tract, and urinary system.
8 s one of the most common cancer types in the urinary system.
9 exploited to direct cancer therapies to the urinary system.
10 Elimination was via the hepatobiliary and urinary system.
11 Elimination was via the hepatobiliary and urinary systems.
12 ed functional recovery of both locomotor and urinary systems.
13 he respiratory, digestive, reproductive, and urinary systems.
14 n and was excreted via the hepatobiliary and urinary systems.
15 ersaturation leads to stone formation in the urinary system, affects about 5%-10% of individuals worl
16 74.2% (1120/1509) of the ESFs involved the urinary system among which 79.6% (892/1120) were renal c
17 A) is the most common malignant tumor of the urinary system and is characterized by high metastatic r
19 lammation relates to inflammation within the urinary system and specifically the bladder and/or prost
22 chromosomal anomalies, 93.2% (91.6-94.5) for urinary system anomalies, 83.2% (79.8-86.0) for digestiv
23 ulated as the iomeprol excretion rate in the urinary system between arterial and excretory phases (Ho
24 ns into the pathophysiological states of the urinary system, but first, detailed characterization of
28 nifests as recessive phenotypes in the upper urinary system, cardiac venous pole, inner ear, and axia
29 s, the disease primarily affected the genito-urinary system, compatible with sexual transmission, whe
30 nosis of abnormalities of abdominal wall and urinary system, consideration of urachal abnormalities i
32 ticular craniofacial, upper limb, heart, and urinary system defects that are present in approximately
33 nd antifungal medicines, drugs affecting the urinary system, drugs affecting the respiratory system,
35 of the most common malignant cancers of the urinary system, identification of BC cell growth-associa
39 also observed for symptoms/disorders of the urinary system (OR 1.36, 95% CI 1.19-1.56), asthma (OR 1
41 sive drug delivery approach that targets the urinary system overcomes the current barriers facing eff
42 ide evidence of participation of PARs in the urinary system, provide a working model for mast cell tr
43 The kidneys are the main organ of the human urinary system, responsible for filtering the blood, and
44 he rapid clearance of its metabolites to the urinary system suggest that 18F-annexin V will be useful
45 iated with other congenital anomalies of the urinary system; therefore a full evaluation of the urina
46 hra is a flow-enhancing device, enabling the urinary system to be scaled up by a factor of 3,600 in v
49 nd c-Ret expression in the developing genito-urinary system, we postulate that Pax2 is necessary for
51 r (BCa) is the most common malignancy of the urinary system with increasing incidence, mortality, and